EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Delayed drug hypersensitivity reactions: How p-i transforms pharmacology into immunology

Werner J Pichler

Allergology International · 2025-01 · 74 (1) · 33-41

DOI: 10.1016/j.alit.2024.08.006 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Allergology International, 2025-01. Verfasst von Werner J Pichler. Beteiligte Einrichtung: ADR-AC GmbH, Holligenstr. 91, 3008 Bern, Switzerland. Electronic address: werner.pichler@adr-ac.ch. Hauptthemen laut MEDLINE: Hypersensitivity, Delayed, Drug Hypersensitivity. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Delayed drug hypersensitivity reactions (dDHRs) are iatrogenic diseases, which are mostly due to non-covalent interactions of a drug with the immune receptors HLA and/or TCR causing T-cell activation. This is also known as pharmacological interaction with immune receptors or p-i. P-i activation differs from classical antigen-driven immune reactions: a) drug binding induces structural changes in TCR-HLA proteins which make them look like allo-like TCR-HLA-complexes, able to elicit allo-like stimulations of T cells with cytotoxicity and IFNγ production, notably without the involvement of innate immunity; b) drug binding to TCR and/or HLA can increase the affinity of TCR-HLA interactions, which may affect signaling and IL-5 production by CD4+ T cells, and thus contribute to eosinophilia commonly found in dDHRs or induce oligoclonal T cell expansions; c) Both, antigen and p-i stimulations can induce eosinophil- or neutrophil-rich inflammations; but these stimulations should be distinguished as their underlying mechanism and development differ; and d) p-i stimulation can - like graft versus host reactions - result in long-lasting T-cell activations, which can lead to viremia, occasional autoimmunity, or a new syndrome characterized by multiple drug hypersensitivity (MDH). In summary, dDHRs are not allergic reactions but represent peculiar T-cell activations, similar to allo-like stimulations. Understanding and considering the p-i mechanism is needed for preventive measures and optimal treatments of dDHR. In addition, it may help to understand TCR signaling, alloreactivity, and may even open a new way of specific immune stimulations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypersensitivity, DelayedDrug HypersensitivityHumansReceptors, Antigen, T-CellLymphocyte ActivationAnimalsHLA AntigensT-Lymphocytes

Stichwörter der Autor:innen

AlloreactivityCytotoxicityDrug hypersensitivityEosinophiliap-i mechanism

Substanzen

Receptors, Antigen, T-CellHLA Antigens

Autor:innen und Institutionen

  • ADR-AC GmbH, Holligenstr. 91, 3008 Bern, Switzerland. Electronic address: werner.pichler@adr-ac.ch.

Zitieren

APA

Pichler, W. J. (2025). Delayed drug hypersensitivity reactions: How p-i transforms pharmacology into immunology. Allergology International, 74(1), 33-41. https://doi.org/10.1016/j.alit.2024.08.006

Vancouver

Pichler WJ. Delayed drug hypersensitivity reactions: How p-i transforms pharmacology into immunology. Allergology International. 2025;74(1):33-41. doi:10.1016/j.alit.2024.08.006

BibTeX
@article{Pichler2025,
  author = {Pichler, Werner J},
  title = {Delayed drug hypersensitivity reactions: How p-i transforms pharmacology into immunology},
  journal = {Allergology International},
  year = {2025},
  volume = {74},
  number = {1},
  pages = {33--41},
  doi = {10.1016/j.alit.2024.08.006}
}
Kostenlos starten →